You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

1544 Results
Document
New
May 2025
Document
New
May 2025
Document
New
May 2025
Document
New
May 2025
Document
New
May 2025
Document
New
May 2025
Document
New
May 2025
Document
New
May 2025
Document
New
May 2025
Document
New
May 2025
This hub contains tools and resources for primary care providers, colposcopists and other health care providers. This material supports the Ontario...
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    prednisone
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Aggressive Histology Lymphoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
prednisone,
riTUXimab,
polatuzumab vedotin (Unfunded),
DOXOrubicin,
cyclophosphamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2025

Pages